Dianthus Therapeutics CFO sells 124,042 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Dianthus Therapeutics, Inc. EVP, CFO & CBO Ryan Savitz exercised options for 124,042 common shares from November 9 through November 12, 2026, and sold 124,042 common shares over the same dates. Option exercise prices were $8.44, $17.88, $21.77 and $22.07 per share. The transactions were made under a Rule 10b5-1 trading plan adopted August 7, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F12 | 1,339 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F13 | 16,385 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,339 | $21.77 | $29K |
| Exercise | Common Stock F1 | 16,385 | $22.07 | $362K |
| Sale | Common Stock F1, F10 | 17,724 | $90.56 | $1.61M |
| Exercise | Stock Option (Right to Buy) F1, F12 | 1,744 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F13 | 1,300 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,744 | $21.77 | $38K |
| Exercise | Common Stock F1 | 1,300 | $22.07 | $29K |
| Sale | Common Stock F1, F9 | 3,044 | $90.03 | $274K |
| Exercise | Stock Option (Right to Buy) F1, F12 | 1,301 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F13 | 1,260 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,301 | $21.77 | $28K |
| Exercise | Common Stock F1 | 1,260 | $22.07 | $28K |
| Sale | Common Stock F1, F8 | 2,561 | $90.14 | $231K |
| Exercise | Stock Option (Right to Buy) F1, F11 | 29,276 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F12 | 20,608 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F13 | 40,430 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F14 | 10,399 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 29,276 | $17.88 | $523K |
| Exercise | Common Stock F1 | 20,608 | $21.77 | $449K |
| Exercise | Common Stock F1 | 40,430 | $22.07 | $892K |
| Exercise | Common Stock F1 | 10,399 | $8.44 | $88K |
| Sale | Common Stock F1, F2 | 300 | $85.16 | $26K |
| Sale | Common Stock F1, F3 | 700 | $86.70 | $61K |
| Sale | Common Stock F1, F4 | 1,736 | $88.84 | $154K |
| Sale | Common Stock F1, F5 | 37,517 | $90.12 | $3.38M |
| Sale | Common Stock F1, F6 | 58,396 | $90.90 | $5.31M |
| Sale | Common Stock F1, F7 | 2,064 | $91.59 | $189K |
Footnotes (14)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2026.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.09 to $85.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.36 to $87.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.21 to $89.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.44 to $90.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.44 to $91.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.46 to $92.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F8. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F9. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F10. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F11. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F12. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F13. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F14. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.